Podcasts about european association

In this episode Cath was joined by Dr Kathrin Stauffer. They chatted about how the body remembers in multiple ways and how not getting what we need in childhood impacts multiple systems in our bodies (not just the nervous system). When we are on a healing journey the expression of sadness and grieving are an important part of this journey. However, it may be that we are blocked from crying by our defences. We dived into this and talked about food, body shape, body psychotherapy, the the function of comfort eating, shame and much more. Kathrin Stauffer PhD, UKCP Registered Body Psychotherapist, is the author of ‘Emotional Neglect and the Adult in Therapy: Lifelong Consequences to a Lack of Early Attunement' (W.W. Norton 2020).Kathrin was born and educated in Switzerland. Originally a research biochemist, she retrained at the Chiron Centre for Body Psychotherapy. She lives in Cambridge in the UK and works in private practice as a body and humanistic psychotherapist, EMDR practitioner, trainer and supervisor. She previously wrote ‘Anatomy & Physiology for Psychotherapists: connecting Body & Soul' (W.W. Norton 2010). Currently she is the President of the European Association for Body Psychotherapy EABP.You can contact her via her website which is www.stauffer.co.uk.If you're enjoying this podcast. Please leave a review and rate the podcast, this really helps others to find it.To sign up for the journal prompts and Nurture.Heal.Grow (on Substack) please head to www.cathcounihan.com or @cathcounihan on Instagram. Follow Cath on social media here:Instagram: @cathcounihanSubstack: Nurture.Heal.GrowFacebook: Cath Counihan Hosted on Acast. See acast.com/privacy for more information.

In this episode Cath is joined by Dr. Kathrin Stauffer for a rich and varied discussion about emotional neglect, what causes this, how we might know we have been emotionally neglected, the interplay with narcissistic family dynamics, what constitutes narcissistic traits and how narcissism and perfectionism can play out in motherhood. Kathrin Stauffer PhD, UKCP Registered Body Psychotherapist, is the author of ‘Emotional Neglect and the Adult in Therapy: Lifelong Consequences to a Lack of Early Attunement' (W.W. Norton 2020). She was born and educated in Switzerland. Originally a research biochemist, she retrained at the Chiron Centre for Body Psychotherapy. She lives in Cambridge in the UK and works in private practice as a body and humanistic psychotherapist, EMDR practitioner, trainer and supervisor. Currently she is the President of the European Association for Body Psychotherapy EABP. Kathrin's website is www.stauffer.co.uk If you wish to work with Kathrin or have a question for her, then email her direct on kathrin@stauffer.co.ukIf you're enjoying this podcast. Please leave a review and rate the podcast, this really helps others to find it.To sign up for the journal prompts and Nurture.Heal.Grow (on Substack) please head to www.cathcounihan.com or @cathcounihan on Instagram. Follow Cath on social media here:Instagram: @cathcounihanSubstack: Nurture.Heal.GrowFacebook: Cath Counihan Hosted on Acast. See acast.com/privacy for more information.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Marc Pelletier, division chief of cardiac surgery for the Department of Surgery at Yale School of Medicine, about patient blood management. Chapters 00:00 Intro 01:45 EACTS 2025 07:19 JANS 1, HVD Management Guidelines 16:26 JANS 2, Low-Risk AVR Evidence 19:21 JANS 3, Warden Procedure Selection 20:36 JANS 4, Primary Repair of CAT 21:48 JANS 5, NEWTON-CABG Cardiolink-5 23:20 Video 1, Acute Aortic Syndrome 24:54 Video 2, Redo TVR Under Bypass 27:13 Video 3, Giant Tension Bulla 28:47 Dr. Pelletier Interview 34:25 Outro They delve into the Society of Thoracic Surgeons (STS) guidelines on patient blood management, along with key tips. They also explore preoperative optimization, provide an example, and discuss cell savers and reducing dead space during surgery. Additionally, they touch on postoperative transfusion and the importance of performing meticulous surgery.  Joel also highlights recent JANS articles on the 2025 ESC/EACTS guidelines for the management of valvular heart disease, low-risk aortic valve replacement at the crossroads of evidence, ideal age and weight for the Warden procedure in patients with partial anomalous pulmonary venous return, a systematic meta-analysis of short- and long-term outcomes of the primary repair of common arterial trunk, and an international, randomized, double-blind, placebo-controlled trial on the effect of Evolocumab on saphenous vein graft patency after coronary artery bypass surgery.  In addition, Joel explores the surgical treatment of acute aortic syndrome, a redo tricuspid valve replacement technique under right heart bypass for a previously repaired tricuspid valve, and thoracoscopic resection of a giant tension bulla. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease: Developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)   2.) Low-Risk Aortic Valve Replacement at the Crossroads of Evidence  3.) Is There an Ideal Age or Weight for the Warden Procedure in Patients With Partial Anomalous Pulmonary Venous Return?  4.) Primary Repair of Common Arterial Trunk: A Systematic Meta-Analysis of Short- and Long-Term Outcomes  5.) Effect of Evolocumab on Saphenous Vein Graft Patency After Coronary Artery Bypass Surgery (NEWTON-CABG CardioLink-5): An International, Randomized, Double-Blind, Placebo-Controlled Trial  CTSNet Content Mentioned  1.) Surgical Treatment of Acute Aortic Syndrome   2.) Redo Tricuspid Valve Replacement Technique Under Right Heart Bypass for a Previously Repaired Tricuspid Valve   3.) Thoracoscopic Resection of a Giant Tension Bulla   Other Items Mentioned  1.) STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management  2.) Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials  3.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani  4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Welcome to Ozempic Weightloss Unlocked, the podcast that brings you the latest updates on Ozempic and its growing impact on medicine, health, and lifestyle. I'm your host, and today, we're diving into what's new, what's raising eyebrows, and what may lie ahead for this game-changing drug.Ozempic, also known as semaglutide, was originally developed by Novo Nordisk for the treatment of type two diabetes. Its ability to mimic a hormone called GLP-1 means it helps regulate blood sugar and, as a side effect notable in clinical trials, leads to significant weight loss. The higher-dose version, Wegovy, was later approved specifically for weight management in people who are overweight or living with obesity. According to the European Association for the Study of Obesity, semaglutide and its cousin tirzepatide are now recommended as first-choice treatments for obesity and related complications. This positions these medications at the forefront of modern obesity therapy, even among patients without diabetes.Recently, there has been a surge in the use of GLP-1 drugs like Ozempic among individuals undergoing bariatric surgery. A study presented at the American College of Surgeons Clinical Congress highlighted that in just four years, the number of patients prescribed these medications before surgery jumped from less than two percent to nearly thirty percent. This reflects a major shift in how we approach weight management and preoperative care. More and more, doctors consider these drugs as integral tools not just for diabetes, but also for weight-related conditions in broader populations.The popularity of Ozempic isn't without concern. The Journal of the American Medical Association published findings showing that people taking semaglutide were twice as likely to develop a form of vision loss called neovascular age-related macular degeneration. Researchers from the University of Toronto highlighted that the risk remains relatively small but is real enough for both patients and doctors to take seriously, especially since the biological mechanism makes sense. Semaglutide can affect blood vessels and inflammation—two factors thought to play a role in this kind of vision loss.Other side effects are drawing attention as well. Studies confirm that up to forty percent of the weight lost on semaglutide actually comes from muscle, including the heart muscle—not just fat. The University of Alberta reports that pairing the medication with ketone supplements preserves muscle mass while still achieving fat loss. This could be an avenue for making Ozempic safer, especially for those worried about long-term effects on strength, immunity, and heart health.The list of reported complications is growing. Aside from the more publicized risks of stomach paralysis and vision loss, there is new evidence that Ozempic may increase hair loss, particularly in women. The United States Food and Drug Administration also updated Ozempic's label to include warnings about severe pancreatitis and kidney injuries, underscoring the importance of careful monitoring and open communication with healthcare providers.A major story this year is just how many patients struggle with these side effects. A new study found that most people who start Ozempic discontinue it within a year. High costs, unpredictable insurance coverage, and complications ranging from discomfort to life-threatening injuries are cited as reasons. Lawsuits against Novo Nordisk for insufficient warning of these risks are mounting, and scrutiny from regulators and the courts is escalating.On a positive note, shortages of Ozempic that plagued pharmacies since 2022 appear to be resolved. The Food and Drug Administration removed the drug from its shortage list this year after confirming an increase in production and availability.Exciting research also points to the future—oral versions of GLP-1 drugs are in development, and clinical trials suggest they may offer effective weight loss without the need for injections. Scientists believe these pills could make treatment easier and more accessible for millions more people.As Ozempic's story grows, one thing is clear: both its benefits and risks need to be part of every conversation between patients and their doctors. As always, it's important for anyone considering or currently using Ozempic to stay informed and to consult their healthcare team about new research, risks, and the best individualized plan.Thanks for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe for the latest updates on this evolving landscape. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Contrary to popular belief, peer review has only recently become an integral step in scientific publishing. Currently seen by many as a badge of honour ensuring valid, innovative and honest research, peer review seems in reality to be increasingly thankless, exploitative, and sometimes invisible. How did we get here? In this episode of Communicable, Annie Joseph and Angela Huttner are joined by two experts, Melinda Baldwin (University of Maryland, USA) and Serge Horbach (Radboud University, Netherlands), to unpack and examine the role of peer review, why it is still essential, and how it fits within the greater editorial process. The conversation covers the history of peer review, contemporary formats including open review and the use of artificial intelligence, and thoughtful discussion on how to fix and rethink peer review. This episode was edited by Kathryn Hostettler and peer reviewed by Barbora Píšová from the Czech Republic.Related podcast episodes Communicable episode 13: The Wild West of publishing today—predatory journals and how to deal with them https://share.transistor.fm/s/e3abe9af ResourcesEASE, the European Association of Science Editors https://ease.org.uk/ Peer review week https://peerreviewweek.net/ Further readingCsiszar, A. The Scientific Journal: Authorship and the Politics of Knowledge in the Nineteenth Century. The University of Chicago Press, 2018. DOI: 10.7208/chicago/9780226553375.001.0001 Entradas, Sousa, Yan, et al. (2023) Public Deliberative Workshops – Findings. POIESIS project deliverable D2.2. https://poiesis-project.eu/deliverables/.Ross-Hellauer T and Horbach SPJM. Additional experiments required: A scoping review of recent evidence on key aspects of Open Peer Review, Research Evaluation, 2024. DOI: 10.1093/reseval/rvae004Horbach SPJM and Halffman W. The changing forms and expectation of peer review. Res Integr Peer Rev 2018. DOI: 10.1186/s41073-018-0051-5Danziger S, et al. Extraneous factors in judicial decisions. Proc Natl Acad Sci USA, 2011. DOI: 10.1073/pnas.1018033108Fyfe, A., Moxham, N., McDougall-Waters, J., & Røstvik, C. M. (2022). A History of Scientific Journals: Royal Society publishing, 1665-2015. London: UCL Press.“Misconduct in Science,” 9 February 1983, NN3-443-UD-12D-1 box 78, file “RES 12 Misconduct in Science, 1983-1987,” Papers of the NIH Director, National Archives and Records Administration, College Park, MD.Baldwin M. In Referees We Trust? How Peer Review Became a Mark of Scientific Legitimacy. MIT Press (Open Access). Work in Progress.

THE European Association for the study of obesity has issued new guidelines stating weight loss drugs should be the first treatment for patients. European doctors argue that these jabs can be used as powerful slimming aids and reduce other health concerns such as such as high blood pressure and type 2 diabetes. All to discuss further with Professor Donal O'Shea, Clinical Lead for Obesity at the HSE.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP clinical trials, both of which were presented at the European Association for the Study of Diabetes (EASD) 2025 Conference. 00:00:00 Introduction 00:00:32 ATTAIN-1 00:04:07 GLP-1s as a Daily Pill 00:08:20 Possible Lower GLP-1 Prices 00:09:03 STEP UP 00:11:41 Cardiovascular Protection with GLP-1s 00:12:48 GI Side Effects of Semaglutide 7.2 00:16:16 3 Times the Dose, 3 Times the Cardiovascular Protection? 00:17:20 Outro

Who truly shapes the impact of a professional speaker—the person on stage or the team guiding them behind the scenes? Reflecting on purpose, legacy and kindness, Nick Gold, MD of Speakers Corner, shares his realisation that while he and his team may not be the ones delivering the message on stage, their role in ensuring the right speaker reaches the right audience carries both privilege and responsibility. Nick explores how fun, genuine connection and challenging traditional measures of success inform his approach to business and life. By embracing uncertainty and change with intuition and curiosity, Nick demonstrates his focus on creating meaningful indelible impacts.   KEY TAKEAWAY ‘Through the business, we have an indelible impact on people's lives and that's a responsibility but also that's the purpose.'   ABOUT THE GUEST – NICK GOLD Being a dynamic entrepreneur and business leader is at the heart of everything Nick does. From founding, scaling and growing multiple successful ventures across the speaking industry, he has established a strong track record and he thrives on challenging the status quo, embracing bold ideas and driving innovation to create impactful businesses that inspire and deliver lasting value. Together with his business partner and brother Tim and his other business partner, Michael, they're building businesses which go beyond the transactional nature of booking a speaker. They believe in forming partnerships with their clients, whether they be companies or speakers, to drive meaningful event experiences and deliver tangible value, learning and return on investment.  As an entrepreneur and a speaker industry pioneer, Nick has built and scaled several successful businesses including; Speakers Corner, Speaking Office and Future Voices.  * Speakers Corner is an award winning international speaker bureau that connects organisations with world class talent.  * Speaking Office innovates speaker representation  * Future Voices is a platform designed to help speakers understand the business of speaking and how to improve their speaking through coaching, bureaux insights, positioning and promotion as well as creating a speaker community so that they can grow together.  Nick has been president of the International Association Speaker Bureaus as well as Chair of the European Association of Speaker Bureaus.  CONNECT WITH NICK https://www.linkedin.com/in/nickgold/ https://www.linkedin.com/company/speakers-corner/posts/ https://www.linkedin.com/company/future-voices-speakers/   ABOUT THE HOST - AMY ROWLINSON Amy is a purpose and fulfilment coach, author, podcast strategist and mastermind host who empowers purpose-driven leaders to boost productivity, engagement and meaning in life and work. Through transformational conversations, Amy helps individuals overcome overwhelm and live with clarity, building living legacies along the way.   WORK WITH AMY If you're interested in how purpose can help you and your business, please book a free 30 min call via https://calendly.com/amyrowlinson/call    KEEP IN TOUCH WITH AMY Sign up for the weekly Friday Focus - https://www.amyrowlinson.com/subscribe-to-weekly-newsletter    CONNECT WITH AMY https://linktr.ee/AmyRowlinson    BUY AMY'S BOOK (2025 Business Book Awards Finalist) Focus on Why* by Amy Rowlinson with George F. Kerr – https://amzn.eu/d/6W02HWu    HOSTED BY: Amy Rowlinson   DISCLAIMER The views, thoughts and opinions expressed in this podcast belong solely to the host and guest speakers. Please conduct your own due diligence.  *As an Amazon Associate, Amy earns from qualifying purchases.  

Welcome to Ozempic Weightloss Unlocked, the podcast where the science and the stories around Ozempic are put into focus for anyone curious about medical breakthroughs, health, and real-world results. Today we dive into the latest findings shaking up the world of weight management with Ozempic, a brand name for semaglutide. New research published mid-September in The Lancet Diabetes & Endocrinology shows that a triple-sized weekly dose of Ozempic—specifically 7.2 milligrams—helped people with obesity lose even more weight than the currently approved lower dose. Adults who took this higher dose lost on average nearly 19 percent of their body weight. Nearly half of participants on this regimen lost at least 20 percent, and a third lost a quarter or more. Similar benefits were seen for those with type 2 diabetes, with the higher dose leading to a 13 percent weight loss, compared to 10 percent for the lower dose.But there is more than just the numbers on the scale. Participants on the higher dose saw improvements in waist circumference, blood pressure, blood sugar, and cholesterol numbers. Importantly, the higher dose was found to be both safe and generally well tolerated. The most frequent issues were digestive, like nausea and diarrhea, but these tended to resolve over time with no increased risk of severe low blood sugar or other serious events. Researchers from the Wharton Medical Clinic in Canada concluded that even greater health improvements could be reached in the future, but they called for more research into the long-term effects and safety as use expands.Adding to the buzz, a recent study out of Denmark raises important questions about how long people actually stick with Ozempic for weight management. According to research presented at the Annual Meeting of The European Association for the Study of Diabetes, more than half of adults who began using the drug for weight loss ended up quitting within one year. Factors behind this drop-off included cost, side effects, and potential health complications. When treatment is stopped, most people regain weight, highlighting that Ozempic is not a short-term fix and needs to be taken long term for sustainable results. The findings raise red flags since discontinuing the medication can undermine hard-won health improvements, and the high price also risks making access unequal.Ozempic is not just for the scale—it has heart-protective effects too. Novo Nordisk, the pharmaceutical company behind the drug, released results from the REACH trial showing that once-weekly Ozempic reduced the risk of heart attack, stroke, or hospitalization for heart failure by a significant 25 percent compared to an older medication called dulaglutide. That is a substantial bonus, especially for those with both obesity and cardiovascular risk factors.Researchers are also learning that how you eat can affect how well Ozempic works. A team from Kyoto University found that people who eat in response to sights and smells of food are more likely to see weight loss benefits from Ozempic, compared to those who eat mainly for emotional reasons. Those with emotional eating patterns might require additional behavioral or psychological support for the medication to be most effective.The science is clear—GLP-1 receptor agonists like Ozempic can be life-changing, delivering substantial and safe weight loss, along with significant improvements for blood sugar, heart health, and metabolic risk factors. But to sustain progress, long-term commitment is key, and the therapy works best alongside changes in eating habits and ongoing support.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found today's update helpful, be sure to subscribe for more news and expert insights on this quickly evolving topic. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome back to Ozempic Weightloss Unlocked, the podcast where we dive into the latest news and analysis about one of the most talked-about treatments for weight loss and metabolic health.Let us jump right in with some breaking research. According to The Lancet Diabetes and Endocrinology, new clinical trial data shows that a triple-dose of Ozempic, meaning 7.2 milligrams weekly, resulted in almost nineteen percent average weight loss in adults without diabetes. That is a substantial jump compared to the sixteen percent with the standard 2.4 milligram dose, and only around four percent with a placebo. Nearly half of those on the higher dose lost at least twenty percent of their body weight, and a third saw weight reductions of twenty-five percent or more. Even among adults with type 2 diabetes, the higher dose achieved thirteen percent weight loss, compared to ten percent with the lower dose. Waistlines, blood pressure, blood sugar, and cholesterol all improved on the higher dose. Safety remained solid, with the most common side effects being manageable nausea and diarrhea that usually settled down over time. Importantly, there was no increase in serious adverse events.Now, for lifestyle impacts and long-term use. A population-wide study presented at the European Association for the Study of Diabetes reports that half of people who start Ozempic for weight loss stop taking it within a year. Cost is a major factor, with the lowest dose costing around two thousand Euros a year in some areas. Younger adults and people from lower income neighborhoods were far more likely to discontinue, likely due to financial barriers. Adverse effects like nausea, and pre-existing conditions, played a role as well. The study found that men were more likely to stop early than women, and adherence was especially hard for those with a history of psychiatric conditions or chronic illness. That is concerning, since people with these conditions often need the benefits the most. Once people stop the medication, weight is often regained, showing just how important it is to find sustainable approaches to weight management.On the topic of who benefits most, a study in Frontiers in Clinical Diabetes and Healthcare highlighted that emotional eating can reduce the effectiveness of Ozempic. The medication is best for people who overeat due to external cues like the smell or appearance of food, rather than for those who eat in response to boredom, anxiety, or sadness. Health experts now recommend that healthcare providers assess a person's relationship with food before prescribing Ozempic or its counterparts. If emotional eating is a primary issue, psychological support may be necessary alongside medication.For those worried about cardiovascular risks, the REACH study presented at the annual meeting of the European Association for the Study of Diabetes confirmed that Ozempic stands out for reducing cardiovascular risk, even among those with multiple chronic conditions. Large-scale, real-world data reinforce its value, particularly in older populations who often have comorbidities like heart disease.Let us also touch on a warning that has emerged: rapid weight loss with medications like Ozempic can cause muscle loss, particularly in women and older adults. While the fat loses fast, it is essential to protect muscle mass with diet and exercise. Experts stress that lifestyle habits—good nutrition, adequate sleep, and physical activity—remain crucial for long-term results, even when taking medication.To sum up, Ozempic continues to make headlines for its effectiveness, but sticking with the medication is a challenge for many due to cost, side effects, and complex eating habits. Emotional and physical health both need to be addressed for the best outcomes. As always, open discussion with healthcare professionals about individual goals, potential barriers, and long-term maintenance is vital.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss an episode. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic and similar medications have remained at the center of the weight loss conversation this week, with new studies and high-profile voices like Oprah Winfrey bringing both excitement and nuanced caution. Major clinical research just published in a leading medical journal demonstrates that higher, triple doses of semaglutide, sold under names like Ozempic and Wegovy, are driving even more significant weight loss in people with obesity. According to researchers led by Dr Sean Wharton at a leading Canadian weight management clinic, adults without diabetes who took the highest 7 point 2 milligram dose weekly saw an average weight loss approaching nineteen percent of their body weight, notably higher than what's been seen with typical doses. Nearly half of those patients lost twenty percent or more of their body weight in these trials, suggesting very real potential for those struggling with severe obesity. The same trials found that people with type two diabetes saw weight drops of thirteen percent using the highest dose. Importantly, the higher dose still appeared safe and generally well tolerated, with common side effects including nausea and diarrhea that mostly resolved over time. The study did not find a higher risk of dangerous drops in blood sugar or other serious complications. These results are meaningful because they expand the promise of these drugs for patients not reaching their goals on standard doses. However, experts stress that further research is essential to fully understand the long term effects of such a powerful regimen and whether the benefits continue to outweigh any risks as time goes on.Beyond the numbers, more people are sharing their personal stories about these new drugs, and Oprah Winfrey continues to be among the most influential. In new interviews and her recent podcast episode, Oprah has confirmed that she uses a prescription GLP dash 1 agonist, the same class of medication as Ozempic, as part of her ongoing wellness journey. She has not named the specific brand, but her openness has made it clear that for her, this is not just a quick fix or shortcut. Instead, Oprah describes the decision as a mental shift—acknowledging obesity as a chronic disease that is best managed with a partnership between lifestyle changes and medical treatment. She has been explicit that the medication alone is not magic. Oprah credits her progress to a holistic routine that includes daily exercise, often hiking three to five miles, planful eating with her last meal in the late afternoon, and close attention to water intake and overall health habits. She has left behind the self blame that characterized her earlier struggles and now uses her platform to challenge the idea that using medication means failure. Instead, she frames it as using every available tool responsibly—paired with self compassion and ongoing commitment.As these drugs become more widely used, big questions remain. A new RAND Corporation report finds that nearly one in eight Americans have tried Ozempic or a similar medication. Use is particularly high among women aged fifty to sixty four. Yet significant numbers report troublesome side effects—most commonly nausea and diarrhea—though these are usually manageable. There are persistent concerns about access and continuity, too. Research just presented at the European Association for the Study of Diabetes finds that about half of patients stop using these drugs within a year, mostly due to high cost, with prices remaining out of reach for many, especially younger people and those with lower incomes. Muscle loss, especially among older adults and women, is another emerging potential downside discussed in the latest studies, reminding users to stay mindful of their overall health—not just what the scale shows. And despite the massive popularity, there are still new legal warnings and lawsuits over rare but serious complications, such as gastroparesis, which can slow digestion to a dangerous degree. The US Food and Drug Administration has continued to update warning labels as new risks are identified.For listeners considering this medication, the message from both doctors and people like Oprah is clear. Ozempic and its cousins can be life changing, but only as part of a larger strategy, with realistic understanding of the risks and the need for sustained healthy habits. Science is still catching up to the real life experience of millions as both hope and caution shape the next chapter of the weight loss revolution.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Happy September! This month for the September 2025 episode of the RCEM Learning Podcast Andy and Dave are talking about AI interpretation of ECG findings and managing acute asthma exacerbations. We are then going back to Becky and Chris rounding off the second part of their guideline on atrial fibrillation. We'll then end with New Online. If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:13) New in EM - AI vs doctor in cath lab activations Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (Queen of Hearts by PMcardio) (Shroyer et al., 2025) (18:00) Guidelines for EM - ESC Atrial Fibrillation (Part Two) ESC - 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (ESC, 2024) (39:03) New in EM - Management of acute asthma exacerbations As-Needed Albuterol–Budesonide in Mild Asthma (LaForce et al., 2025) Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma (Cochrane Library, 2021) (54:00) New Online – new articles on RCEMLearning for your CPD Understanding Medical Cannabis: Mechanisms, Indications and Clinical Integration - David Tang Safe Sedation Procedures in Adults - Duncan Russell and Shobhan B Thakore Unusual Agitation in Final Year Student - Cathy Wield and Mark Horowitz

A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. from China, and pharma companies exit the U.K. in droves. President Donald Trump is reportedly writing an executive order that would clamp down on the pharmaceutical industry's ability to buy new molecules from biotechs based in China, while Sanofi, Merck and more have canceled or suspended investments in the U.K. following a sizeable increase in a mandatory levy in the region. In other business news, Novo Nordisk's newly appointed CEO Maziar Mike Doustdar hit the ground running, cutting around 9,000 employees and informing those who remained that they would need to return to the office. Novo's headcount had climbed 81% in five years as its revenue soared—and then fell. The obesity juggernaut has been a key presence at the European Association for the Study of Diabetes' annual meeting this week, announcing that it would seek FDA approval for a high-dose formulation of Wegovy, and presenting new data for long-acting amylin analog cagrilintide. Meanwhile, Reuters reported that Eli Lilly's orforglipron could potentially qualify for the FDA's recently launched Commissioner's Priority Voucher, which could see the oral obesity candidate approved this year.  The gene therapy space was hit with more bad news as Capsida Biotherapeutics reported the death of a patient being treated with its investigational gene therapy for epileptic disorders. This follows an unfortunate trend in 2025 that has also seen deaths attributed to Sarepta's approved Duchenne muscular dystrophy gene therapy Elevidys and a monoclonal antibody used for lymphodepletion in a study of Allogene's CAR T cell therapy cema-cell. According to a new analyst survey, however, doctors are still prescribing Elevidys to ambulatory patients.  Meanwhile, on the regulatory front, FDA Center for Drug Evaluation and Research Director George Tidmarsh reportedly told two separate groups last week that he “would like to get away” from advisory committee meetings, but quickly appeared to walk the comments back in a statement to Endpoints News.  Finally, in BioPharm Executive, BioSpace takes a deep dive into the FDA's new crackdown on pharmaceutical drug ads, and spotlights Akeso CEO Michelle Xia who built the biotech from a $3 million angel fundraising round to its current $15 billion valuation.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novartis and Monte Rosa have entered into their second molecular glue deal worth up to $5.7 billion, with Novartis putting $120 million upfront for more of the biotech's AI-discovered degraders. The myasthenia gravis market, once sparse, is now flourishing with new treatments approved and promising late-stage trial results from companies like Argenx and Regeneron. In other news, AstraZeneca has suspended its $270 million commitment in the UK, the FDA has flip-flopped on scrapping advisory committee meetings, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. The myasthenia gravis space is heating up with targeted therapies, with several companies releasing promising late-stage trial results. Biogen is developing a pipeline for lupus, with investors showing interest in their programs. The FDA has several actions scheduled for September, including Merck's proposed subcutaneous formulation of Keytruda. Eli Lilly's obesity pill, Orforglipron, is in focus at the European Association for the Study of Diabetes meeting. In the cancer news, Merck's Keytruda challenger faces consistency problems, while other companies like Daiichi Sankyo and Biontech report positive data. Capsida reports a patient death in a gene therapy trial, while Alkermes shows promise in narcolepsy treatment. FDA is looking to streamline the development of non-opioid painkillers. Various webinars and events are upcoming in the pharma industry. Job opportunities are available at companies like Moderna, Abbvie, and Regeneron. Overall, the biopharma industry is seeing advancements and progress in various therapeutic areas.

Welcome to Ozempic Weightloss Unlocked, your source for the latest news, research, and insights on Ozempic and its impact on weight loss, health, and lifestyle.If you are following updates on Ozempic, recent international studies are shedding a spotlight on why so many are both drawn to and dropping away from this buzzy medication. According to reports from HealthDay and Drugs.com, about half of the adults who start Ozempic for weight loss end up quitting within just one year. For context, a study out of Denmark tracked more than seventy-seven thousand new Ozempic users and found that fifty-two percent gave it up before the year's end. These findings were presented at this year's European Association for the Study of Diabetes meeting in Vienna.So, why are so many discontinuing Ozempic? One major reason is cost. In Denmark, the lowest possible annual dose is over two thousand euros. In the United States, prices can jump to more than one thousand four hundred dollars monthly if uninsured. People in lower-income areas were nearly fifteen percent more likely to quit early. For many, the price tag is simply not sustainable long-term.Side effects are another factor. Drugs.com highlights that those with gastrointestinal conditions, chronic illnesses, or who are taking psychiatric medication are more likely to stop using Ozempic. The Danish study found that people with existing GI issues were nine percent more likely to quit, and those with heart disease or other chronic conditions were ten percent more likely to stop. Furthermore, common side effects like nausea, vomiting, and diarrhea disproportionately drive users to discontinue.Age and gender play a role too. Younger adults were forty-eight percent more likely to stop Ozempic within the first year compared to older users. Men had a twelve percent greater likelihood than women to quit. The study authors note that women tend to see slightly better weight loss results, which might help motivate their continued use.One important medical application is for people living with diabetes. Originally, Ozempic and similar drugs were developed to help manage blood sugar. However, they've gained popularity strictly for weight loss, and over ninety percent of new prescriptions in some studies are written for those without diabetes.Another recent clinical trial, reported by TheJournal.ie, looked at bumping up the standard dose to see if results improve. By tripling the weekly dosage to seven-point-two milligrams, nearly half of trial participants lost at least twenty percent of their body weight. But remember, higher doses may also lead to more side effects and costs.For younger women who are considering Ozempic, caution is warranted. According to researchers at Flinders University, there are hidden reproductive risks for women in their childbearing years. The Medical Journal of Australia reports that most women prescribed Ozempic are not using effective contraception, even though these medications can pose risks during pregnancy and fetal development. Only twenty-one percent of women on Ozempic were using contraception in one large study of more than one-point-six million general practice records. Notably, women with polycystic ovary syndrome were twice as likely to conceive after starting Ozempic, possibly because weight loss can improve fertility. Lead researcher Associate Professor Luke Grzeskowiak states the need for proper counseling on reproductive risks for women starting these drugs.A final point from ScienceDaily is that stopping Ozempic often leads to regaining weight. Because the drug works by curbing appetite and promoting the feeling of fullness, these benefits disappear once you stop. For most, it is not a quick fix but a long-term commitment.As awareness rises, so does the number of questions around cost, access, side effect management, and the balance of risks and benefits. Whether you are considering Ozempic, currently taking it, or simply curious about its role in the future of weight management, keeping up with peer-reviewed research and evolving guidelines from health agencies is crucial.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please remember to subscribe so you do not miss our next update. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Michael Cremo's book Forbidden Archeology, coauthored with Richard Thompson, caused shock waves in the world of science, It exposed evidence for a human presence on this planet going much further back in time than the current dominant consensus in the world of science allows.In Extreme Human Antiquity, Cremo builds on the foundation of Forbidden Archeology, introducing explosive new cases from all phases of archeological research, from the nineteenth century to the present. Drawing on his knowledge of the history and philosophy of science, he documents how evidence for extreme human antiquity has been subjected to a process of knowledge filtration, by which this evidence is ignored, forgotten, set aside, or dismissed on flimsy grounds.Evidence for extreme human antiquity includes human bones, human footprints, and human artifacts. Cremo's understanding of what counts as human includes discoveries that have previously been attributed to Neanderthals and other hominin species. Cremo presents for each case the pros and cons for taking it as evidence for extreme human antiquity and lets readers make their own decision.MICHAEL A. CREMO is an independent historian of archeology. He is a member of the World Archaeological Congress and the European Association of Archaeologists. Cremo is the principal author of the book Forbidden Archeology, a comprehensive historical survey of archaeological anomalies. Cremo examines the history of the archeology from the standpoint of alternative worldviews, particularly worldviews with foundations in ancient Indian thought. He has given invited lectures on his work at the Royal Institution in London, the anthropology department of the Russian Academy of Sciences in Moscow, the archeology department of the Ukrainian Academy of Sciences, the Indian Institute of Science in Bangalore and many other scientific institutions. He has also lectured on his work at universities throughout the world. He is a frequent guest on radio and television programs, and has a wide presence on the web. His website is www.mcremo.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer. We are joined today by trial PI Veeru Kasivisvanathan (Urologist, UCL, London), and Francesco Giganti (Radiologist, UCL, London), to discuss the findings and what this means going forward. And it is all good news!Your host Declan Murphy is on his own today while Renu Eapen on the road in Singapore. Even better on our YouTube channelLinks below:JAMA paper published todayTwitter:  @compassurology @veerukasi @giga_fraWebsite: compassurology.orgFunders:John Black Charitable Foundation, Prostate Cancer UK, European Association of Urology Research Foundation, Wolfgang.Dieckmann Foundation.

Programul Zebra, live de la Ateneul Român. În cea de-a doua oră a ediției speciale dedicate Festivalului George Enescu, discutăm cu Cristina Uruc, manager Artexim și președinta European Association of Artist Managers, alături de Cătălin Sava, muzicolog și jurnalist cultural.

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Happy August! This month for the August 2025 episode of the RCEM Learning Podcast Andy returns to discuss the investigation of acute coronary syndrome in the ED. Becky and Chris begin a two part deep dive through a guideline looking at the management of atrial fibrillation. We then talk to Matt Reed about the RCEM Flagship Conference and we then end with New Online! If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:28) New in EM - Ruling out ACS in the ED Acute coronary syndrome rule-out strategies in the emergency department: an observational evaluation of clinical effectiveness and current UK practice (Trainee Emergency Research Network, 2025) (19:43) Guidelines for EM - Atrial Fibrillation (European Society of Cardiology) European Society of Cardiology - 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO) (ESC, 2025) (47:26) Matt Reed and the Flagship Conference RCEM - Flagship Conference 2026 (58:28) New Online – new articles on RCEMLearning for your CPD Kishan Indrakumar, Thomas Moore, Mayank Nagar, Preetibah Ratenavelu, Dominique Tirian - Chemical Eye Injuries in the ED Katy Guy, Olivia Curtis-Hughes - Sports-Related Concussions in the Emergency Department Susan Elizabeth Dorrian, Sarah Jones - Disturbed or Psychiatric Patients in the ED Additional Links RCEM - SECEM Conference 2025

The Light Gate welcomes guest: researcher/author Michael Cremo Date: August 18, 2025. Time: 5-7pm pacific / 8-10pm eastern Episode: 121 Discussion: “Forbidden Archaeology” Tonight, The Light Gate is honoured and delighted to welcome researcher and author, Michael Cremo to the show. Born in 1948, Michael knew from a very early age (after spelling out words in his alphabet soup” that he wanted to be a writer. As he says, "From the very beginning, my life has been a spiritual quest for love and truth. My father served as an American Intelligence Officer for the United States Air Force, and from that time my life was one of periodic change and travel. I went to high school at an American school in Germany and spent my vacations traveling all over Europe. Once, in the spring of 1965, in a youth hostel in Stockholm, I met some kids who had been to India and back, traveling overland. I decided I would someday do the same thing.” He became interested in Eastern philosophy and Indian esoteric teachings , and studied the Bhagavad-gita.” By 1980, he had established himself as a writer, and since then his many books have sold more than 10 million copies and have been translated into many languages. His first book, “Forbidden Archaeology: the Hidden History of the Human Race,” was a landmark book challenging the mainstream paradigm of archeology and showing that humankind is tens of thousands of years old, but millions. As Michael writes, “This book shows that archaeologists and anthropologists, over the past one hundred and fifty years, have accumulated vast amounts of evidence showing that humans like ourselves have existed on this planet for tens of millions of years. We show how this evidence has been suppressed, ignored, and forgotten because it contradicts generally-held ideas about human evolution." Some of his other books include “My Science, My Religion,” “Human Devolution,” “The Forbidden Archeologist,” “Extreme Human Antiquity,” and more! Michael Cremo is a member of the World Archeological Congress and the European Association of Archaeologists as well as an associate member of the Bhaktivedanta Institute specializing in history and philosophy of science. LINKS: Website: https://www.mcremo.com/

In this episode, Dr. Linda Chu explores a major Radiology consensus statement on optimizing CT angiography for suspected pulmonary embolism. The discussion covers advanced imaging techniques, key considerations for special populations, and standardized reporting practices to improve diagnostic clarity and patient outcomes. Optimal Approach to Performing and Reporting ComputedTomography Angiography for Suspected Acute PulmonaryEmbolism: A Clinical Consensus Statement of the ESC Working Groupon Pulmonary Circulation & Right Ventricular Function, the FleischnerSociety, the Association for Acute Cardiovascular Care (ACVC) andthe European Association of Cardiovascular Imaging (EACVI) of theESC, Endorsed by European Respiratory Society (ERS), Asian Societyof Thoracic Radiology (ASTR), European Society of Thoracic Imaging(ESTI), and Society of Thoracic Radiology (STR). Radiology 2025; 315(3):e243833.

This episode is brought to you by HalloCasa, the SEO-ranked digital business card for real estate agents. Looking to find the right agent, no matter where you are?Visit https://home.hallocasa.com to discover and connect with top real estate agents globally.Explore and get started today: https://hallocasa.com/brokers In this episode, we talk with Maria-Alexandra Mihăilă, EU & International Affairs Manager at CEPI – the European Association of Real Estate Professions. Based in Brussels, Maria-Alexandra brings deep expertise in European diplomacy, international relations, and real estate regulation.We explore:1. How CEPI engages with EU institutions like the European Commission and Parliament2. How national and local real estate associations are represented at the EU level3. CEPI's policy paper on affordable housing4. The fight against money laundering in EU real estate5. The MMCEPI Certification for real estate professionals6. Maria-Alexandra's vision for the future of cross-border real estate cooperationWhether you're a policymaker, real estate professional, or passionate about EU policy, this episode offers key insights into how CEPI is shaping the European real estate landscape.Chapters:00:01:15 – Introduction00:08:00 – Work with the European Commission & Parliament00:13:45 – Representing Local & National Associations00:21:50 – CEPI's Collaborations at the EU Level00:24:00 – Policy Paper on Affordable Housing00:31:30 – Anti-Money Laundering in EU Real Estate00:35:00 – Future Vision & MMCEPI Certification00:37:22 – Conclusion & Final ThoughtsLearn more about CEPI: https://www.cepi.eu

Ghana's twentieth century was one of dramatic political, economic, and environmental change. Sparked initially by the impositions of colonial rule, these transformations had significant, if rarely uniform, repercussions for the determinants of good and bad nutrition. All across this new and uneven polity, food production, domestic reproduction, gender relations, and food cultures underwent radical and rapid change. This volatile national history was matched only by the scientific instability of nutritional medicine during these same years. Moving between the dry Northern savannah, the mineral-rich and food-secure Southern rainforest, and the youthful, ever-expanding cities, John Nott's Between Feast and Famine: Food, Health, and the History of Ghana's Long Twentieth-Century (UCL Press, 2025) is a comparative history of nutrition in Ghana since the end of the nineteenth century. At the heart of this story is an analysis of how an uneven capitalist transformation variously affected the lives of women and children. It traces the change from sporadic periods of hunger in the nineteenth and early twentieth centuries, through epidemics of childhood malnutrition during the twentieth century, and into emergent epidemics of diet-related non-communicable disease in the twenty-first century. Employing a novel, critical approach to historical epidemiology, Nott argues that detailing the co-production of science and its subjects in the past is essential for understanding and improving health in the present. John Nott is a Research Fellow in Science, Technology and Innovation Studies at the University of Edinburgh. His research interests sit primarily across the history of medicine and economic history, with a particular focus on colonial and postcolonial contexts. He also has complementary interests in medical anthropology and STS, and is currently a Research Fellow on Lukas Engelmann's ERC-funded project, "The Epidemiological Revolution: A History of Epidemiological Reasoning in the Twentieth Century." Amongst other things, he is working on a monograph detailing the economic and medical history of surveillance in Anglophone Africa. Dr. Nott is also the Principal Investigator of a collaborative British Academy-funded project, "Population Health in Practice: Towards a Comparative Historical Ethnography of the Demographic Health Survey," which explores the history and contemporary production of epidemiological and demographic data in Ghana, Tanzania, and Malawi. Dr. Nott was trained at the University of Leeds, where his PhD focused on the history of nutrition and nutritional medicine in Ghana since the end of the nineteenth century. Immediately before coming to Edinburgh, he was a fellow at the Merian Institute for Advanced Studies in Africa (MIASA) at the University of Ghana. Before this, Dr. Nott was based at Maastricht University as a Research Fellow on Anna Harris' ERC-funded project, “Making Clinical Sense: a Historical-Ethnographic Study of the Technologies Used in Medical Education. The edited collection, “Making Sense of Medicine: Material Culture and the Reproduction of Medical Knowledge,” recently won the Amsterdamska Award by the European Association for the Study of Science & Technology (EASST). You can learn more about his work here. Afua Baafi Quarshie is a Ph.D. candidate in history at the Johns Hopkins University. Her research focuses on mothering and childhood in post-independence Ghana. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Ghana's twentieth century was one of dramatic political, economic, and environmental change. Sparked initially by the impositions of colonial rule, these transformations had significant, if rarely uniform, repercussions for the determinants of good and bad nutrition. All across this new and uneven polity, food production, domestic reproduction, gender relations, and food cultures underwent radical and rapid change. This volatile national history was matched only by the scientific instability of nutritional medicine during these same years. Moving between the dry Northern savannah, the mineral-rich and food-secure Southern rainforest, and the youthful, ever-expanding cities, John Nott's Between Feast and Famine: Food, Health, and the History of Ghana's Long Twentieth-Century (UCL Press, 2025) is a comparative history of nutrition in Ghana since the end of the nineteenth century. At the heart of this story is an analysis of how an uneven capitalist transformation variously affected the lives of women and children. It traces the change from sporadic periods of hunger in the nineteenth and early twentieth centuries, through epidemics of childhood malnutrition during the twentieth century, and into emergent epidemics of diet-related non-communicable disease in the twenty-first century. Employing a novel, critical approach to historical epidemiology, Nott argues that detailing the co-production of science and its subjects in the past is essential for understanding and improving health in the present. John Nott is a Research Fellow in Science, Technology and Innovation Studies at the University of Edinburgh. His research interests sit primarily across the history of medicine and economic history, with a particular focus on colonial and postcolonial contexts. He also has complementary interests in medical anthropology and STS, and is currently a Research Fellow on Lukas Engelmann's ERC-funded project, "The Epidemiological Revolution: A History of Epidemiological Reasoning in the Twentieth Century." Amongst other things, he is working on a monograph detailing the economic and medical history of surveillance in Anglophone Africa. Dr. Nott is also the Principal Investigator of a collaborative British Academy-funded project, "Population Health in Practice: Towards a Comparative Historical Ethnography of the Demographic Health Survey," which explores the history and contemporary production of epidemiological and demographic data in Ghana, Tanzania, and Malawi. Dr. Nott was trained at the University of Leeds, where his PhD focused on the history of nutrition and nutritional medicine in Ghana since the end of the nineteenth century. Immediately before coming to Edinburgh, he was a fellow at the Merian Institute for Advanced Studies in Africa (MIASA) at the University of Ghana. Before this, Dr. Nott was based at Maastricht University as a Research Fellow on Anna Harris' ERC-funded project, “Making Clinical Sense: a Historical-Ethnographic Study of the Technologies Used in Medical Education. The edited collection, “Making Sense of Medicine: Material Culture and the Reproduction of Medical Knowledge,” recently won the Amsterdamska Award by the European Association for the Study of Science & Technology (EASST). You can learn more about his work here. Afua Baafi Quarshie is a Ph.D. candidate in history at the Johns Hopkins University. Her research focuses on mothering and childhood in post-independence Ghana. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-studies

Ghana's twentieth century was one of dramatic political, economic, and environmental change. Sparked initially by the impositions of colonial rule, these transformations had significant, if rarely uniform, repercussions for the determinants of good and bad nutrition. All across this new and uneven polity, food production, domestic reproduction, gender relations, and food cultures underwent radical and rapid change. This volatile national history was matched only by the scientific instability of nutritional medicine during these same years. Moving between the dry Northern savannah, the mineral-rich and food-secure Southern rainforest, and the youthful, ever-expanding cities, John Nott's Between Feast and Famine: Food, Health, and the History of Ghana's Long Twentieth-Century (UCL Press, 2025) is a comparative history of nutrition in Ghana since the end of the nineteenth century. At the heart of this story is an analysis of how an uneven capitalist transformation variously affected the lives of women and children. It traces the change from sporadic periods of hunger in the nineteenth and early twentieth centuries, through epidemics of childhood malnutrition during the twentieth century, and into emergent epidemics of diet-related non-communicable disease in the twenty-first century. Employing a novel, critical approach to historical epidemiology, Nott argues that detailing the co-production of science and its subjects in the past is essential for understanding and improving health in the present. John Nott is a Research Fellow in Science, Technology and Innovation Studies at the University of Edinburgh. His research interests sit primarily across the history of medicine and economic history, with a particular focus on colonial and postcolonial contexts. He also has complementary interests in medical anthropology and STS, and is currently a Research Fellow on Lukas Engelmann's ERC-funded project, "The Epidemiological Revolution: A History of Epidemiological Reasoning in the Twentieth Century." Amongst other things, he is working on a monograph detailing the economic and medical history of surveillance in Anglophone Africa. Dr. Nott is also the Principal Investigator of a collaborative British Academy-funded project, "Population Health in Practice: Towards a Comparative Historical Ethnography of the Demographic Health Survey," which explores the history and contemporary production of epidemiological and demographic data in Ghana, Tanzania, and Malawi. Dr. Nott was trained at the University of Leeds, where his PhD focused on the history of nutrition and nutritional medicine in Ghana since the end of the nineteenth century. Immediately before coming to Edinburgh, he was a fellow at the Merian Institute for Advanced Studies in Africa (MIASA) at the University of Ghana. Before this, Dr. Nott was based at Maastricht University as a Research Fellow on Anna Harris' ERC-funded project, “Making Clinical Sense: a Historical-Ethnographic Study of the Technologies Used in Medical Education. The edited collection, “Making Sense of Medicine: Material Culture and the Reproduction of Medical Knowledge,” recently won the Amsterdamska Award by the European Association for the Study of Science & Technology (EASST). You can learn more about his work here. Afua Baafi Quarshie is a Ph.D. candidate in history at the Johns Hopkins University. Her research focuses on mothering and childhood in post-independence Ghana. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/food

Ghana's twentieth century was one of dramatic political, economic, and environmental change. Sparked initially by the impositions of colonial rule, these transformations had significant, if rarely uniform, repercussions for the determinants of good and bad nutrition. All across this new and uneven polity, food production, domestic reproduction, gender relations, and food cultures underwent radical and rapid change. This volatile national history was matched only by the scientific instability of nutritional medicine during these same years. Moving between the dry Northern savannah, the mineral-rich and food-secure Southern rainforest, and the youthful, ever-expanding cities, John Nott's Between Feast and Famine: Food, Health, and the History of Ghana's Long Twentieth-Century (UCL Press, 2025) is a comparative history of nutrition in Ghana since the end of the nineteenth century. At the heart of this story is an analysis of how an uneven capitalist transformation variously affected the lives of women and children. It traces the change from sporadic periods of hunger in the nineteenth and early twentieth centuries, through epidemics of childhood malnutrition during the twentieth century, and into emergent epidemics of diet-related non-communicable disease in the twenty-first century. Employing a novel, critical approach to historical epidemiology, Nott argues that detailing the co-production of science and its subjects in the past is essential for understanding and improving health in the present. John Nott is a Research Fellow in Science, Technology and Innovation Studies at the University of Edinburgh. His research interests sit primarily across the history of medicine and economic history, with a particular focus on colonial and postcolonial contexts. He also has complementary interests in medical anthropology and STS, and is currently a Research Fellow on Lukas Engelmann's ERC-funded project, "The Epidemiological Revolution: A History of Epidemiological Reasoning in the Twentieth Century." Amongst other things, he is working on a monograph detailing the economic and medical history of surveillance in Anglophone Africa. Dr. Nott is also the Principal Investigator of a collaborative British Academy-funded project, "Population Health in Practice: Towards a Comparative Historical Ethnography of the Demographic Health Survey," which explores the history and contemporary production of epidemiological and demographic data in Ghana, Tanzania, and Malawi. Dr. Nott was trained at the University of Leeds, where his PhD focused on the history of nutrition and nutritional medicine in Ghana since the end of the nineteenth century. Immediately before coming to Edinburgh, he was a fellow at the Merian Institute for Advanced Studies in Africa (MIASA) at the University of Ghana. Before this, Dr. Nott was based at Maastricht University as a Research Fellow on Anna Harris' ERC-funded project, “Making Clinical Sense: a Historical-Ethnographic Study of the Technologies Used in Medical Education. The edited collection, “Making Sense of Medicine: Material Culture and the Reproduction of Medical Knowledge,” recently won the Amsterdamska Award by the European Association for the Study of Science & Technology (EASST). You can learn more about his work here. Afua Baafi Quarshie is a Ph.D. candidate in history at the Johns Hopkins University. Her research focuses on mothering and childhood in post-independence Ghana. Learn more about your ad choices. Visit megaphone.fm/adchoices

José Fernando serves as Founding President of the Global Network of Guarantee Institutions and Special Honorary Chairman of the European Association of Guarantees. He consults for the World Bank and United Nations Development Programme on credit guarantees and green finance. He sits on the Advisory Committee of the European Innovation Council Equity Fund and previously served on its Investment Committee. Fernando led the creation and management of key Portuguese credit guarantee institutions and was President and CEO of PME Investimentos and CFO of IAPMEI. He contributed to the merger forming BPF, the Portuguese Promotional Bank. He is a founder of Knowledge Factory consulting, partner at Quadrantis Capital VC, and winemaker. He holds a degree in Economics, has lectured at universities, and has published works on credit guarantees.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Die Themen in den Wissensnachrichten: +++ Häufige Albträume sind laut Metastudie größerer Risikofaktor als Übergewicht +++ Muster im Zahnzement verraten ob und wie lange wir rauchen +++ Klimawandel könnte Gin-Geschmack verändern +++**********Weiterführende Quellen zu dieser Folge:Frequent nightmares triple risk of early death and accelerate ageing, EAN Congress, 22.06.2025Reconstructing smoking history through dental cementum analysis - a preliminary investigation on modern and archaeological teeth, PLOS One, 27.05.2025Methane-powered sea spiders: Diverse, epibiotic methanotrophs serve as a source of nutrition for deep-sea methane seep Sericosura, PNAS, 16.06.2025Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis, European Heart Journal, 20.05.2025Sources of variance in the volatile contribution of juniper to gin, Journal of the Institute of Brewing, 12.06.2025**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. Key Episode Timestamps 00:00:01 Introduction 00:00:45 Efimosfermin Alfa in MASH 00:05:56 PEth Testing 00:13:19 RETRACT-B 00:20:44 Linerixibat in PBC Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. If you haven't already, be sure to check out part 1 here! Key Episode Timestamps 0:00:00 LITMUS Study 0:05:47 Norursodeoxycholic Acid in PSC 0:10:12 GLOBE Score for PBC 0:15:11 Conclusion Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Shoot us a Text.Episode #1061: China's rare earth restrictions are causing real pain for Europe's automakers, Costco's gas game and checkout tech are stepping up, and American shoppers are oddly calm about rising tariffs—at least for now.Show Notes with links:China's tightened grip on rare earth exports is starting to squeeze Europe's auto manufacturing sector. With critical materials stuck in red tape and only a quarter of export licenses approved, major OEMs and suppliers are bracing for broader production halts in the coming weeks.CLEPA, the European Association of Automotive Suppliers, says hundreds of export license requests were submitted, but only 25% approved since April.Parts plant shutdowns are already affecting suppliers to VW, Mercedes-Benz, BMW, and Bosch.The slowdown stems from China's April decision to suspend exports of rare earths and magnets amid a trade standoff with the U.S.Delays in customs clearance and license processing are compounding the issue, say VDA (the German Automotive Industry Association) and CLEPA.China may ease restrictions for certain European semiconductor firms, but auto remains at risk.“Production delays and even production outages can no longer be ruled out,” said VDA President Hildegard Mueller.America's third-largest retailer is leaning into its members-first model. Costco is expanding hours at gas stations, testing scan-and-go checkout tech, and adding flexible payment options to stay competitive in a tightening retail race.Gas stations now open nationwide until 10 p.m., with select sites opening earlier too.CEO Rob Vachris says the goal is to drive more foot—and fuel—traffic by boosting convenience.Gas accounted for 12% of Costco's total sales in 2024, thanks to exclusive member access and competitive prices.“Scan & Pay” via smartphone is being piloted to streamline checkout, competing with Sam's Club's tech-forward edge.Costco has also teamed with Affirm for monthly payment plans as shoppers look beyond credit cards.A new survey by Modern Retail highlights that while many Americans are concerned about rising costs and tariffs, their spending behavior has yet to shift significantly.76% of surveyed consumers said they were familiar with recent tariffs; over half believe tariffs increase prices for everyday goods.Despite that concern, 40% reported no notable changes in their purchasing habits.A majority of respondents said they were either delaying planned purchases due to higher prices or had already bought items early to avoid anticipated tariff-related cost increases.Electronics and clothing were identified as the most likely categories to see reduced spending.Over half of respondents expressed optimism about their financial outlook for the next six months.Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics. In this episode, recorded live at the European Association for the Study of the Liver Congress (EASL) in Amsterdam, Tom shares invaluable insights into the evolving landscape of hepatology clinical trials and the unique challenges and opportunities shaping the field today. Listen now to stay ahead in the dynamic world of clinical trials.

In this piece we discuss the intricacies of right heart failure, the differences between the right and left ventricles, and the challenges of early detection and monitoring. With a focus upon research we discuss the Swan-Ganz IQ pulmonary artery catheter, with the FastCCO algorithm, from BD Advanced Patient Monitoring. We cover its innovative capabilities, explore its impact on patient care and look particularly at high-risk patients like those with pulmonary hypertension and LVADs. The episode highlights the importance of new monitoring techniques, future research directions, and the promise of continuous data in improving right ventricular function diagnosis and treatment. Presented by Kate Leslie with her guest Joerg Ender, Director of the Department for Anesthesiology and Intensive Care Medicine, Heart Center, Leipzig, Germany. He is second president of the German Society of Anesthesiology and Intensive Care Medicine and former Secretary General of the European Association of Cardiothoracic Anaesthesiologists (EACTA).

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice. Intended for hepatologists, gastroenterologists, and other clinicians managing liver disease, Liver Lineup will unpack the latest research, debate emerging controversies, and spotlight developments that could shape — or sharpen — day-to-day practice, all with unfiltered perspective and clarity. Brown is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University Reau is a professor of internal medicine, the Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and the section chief of Hepatology at Rush University Medical Center. In the inaugural episode, Brown and Reau introduce the mission behind Liver Lineup and share why they created the podcast. Driven by a shared commitment to education, clinical excellence, and elevating the conversation around liver disease, the hosts describe their hope to offer practicing clinicians a clear, concise, and engaging way to keep up with the latest news and innovations in hepatology. They aim to highlight data that's not only new, but meaningful — spotlighting developments that can improve patient care today and shape best practices tomorrow. Together, the Brown and Reau set the stage for what's to come: expert commentary on major liver meetings including Digestive Disease Week, European Association for the Study of the Liver Congress, The Liver Meeting from the American Association for the Study of Liver Diseases, and the American College of Gastroenterology Annual Meeting; coverage of key topics like MASLD, liver cancer, viral hepatitis, and transplant; and conversations with colleagues across the hepatology spectrum. From debates over practice-changing data to discussions on care pathways and diagnostics, Liver Lineup aims to keep clinicians informed, engaged, and ready to translate insight into impact. Looking ahead, Brown and Reau preview upcoming episodes covering major hepatology updates from Digestive Disease Week 2025 and European Association for the Study of the Liver Congress 2025 — with more to follow throughout the year.

As we look ahead to some of the key themes for International HR Day 2025, this episode — recorded at the CIPD Annual Conference and Exhibition 2024 — explores what organisations need to be doing in practical terms to ensure AI becomes a force for good. How are skill requirements expected to evolve over the medium to long term? What role should the profession play in helping organisations navigate change? And finally, is ‘pleasanteeism' really a thing? CIPD Director of Profession David D'Souza is joined by Roisin Walsh, Head of Workforce Capability and Inclusion at Civil Service in Ireland, Radha Barj, Co-Founder and CEO at Rythmik, David Ducheyne, Vice President of European Association for People Management (EAPM). Recorded: CIPD Annual Conference and Exhibition, 7 November 2024

In this episode, we will explore the significance of academic freedom, the challenges it faces globally, and the ways in which researchers and academics can defend and promote this essential liberty. We'll also discuss the broader implications of restricting academic freedom on society and our understanding of various phenomena. Our guest today is Julie Billaud, an Associate Professor of anthropology and sociology here at the Geneva Graduate Institute. Julie is an anthropologist with a background in socio-legal studies. She is also the co-founder and one of the editors of Allegra Lab and is the co-convener of LAWNET (the Network for the Anthropology of Law, Rights and Governance) and a member of the Working Group on Human Rights and Academic Freedom of the European Association of Social Anthropology.

In this episode of the Pre-Hospital Care Podcast, we dive into the crucial role of shared learning within the pre-hospital setting. Learning from past experiences, both successes and challenges, is vital for improving patient outcomes and advancing best practices. We'll explore key moments where shared learning has led to real changes in practice and examine the importance of having a strong central community to ensure that knowledge reaches as many professionals as possible.To explore this topic, we're joined by Sara Orritt, who brings a wealth of experience in emergency medical services and communication. Sara manages the communications and social media for The European Association of Emergency Medical Services (EMS Europe), supports the EMS Europe board in business administration, and helps organise the International EMS Congress. She also works as an Executive Support Officer for Yorkshire Ambulance Service and has previous experience with South East Coast Ambulance Service. Before her career in emergency medical services, Sara worked in television production, including roles with the BBC.Join us as we discuss how shared learning drives change, the role of digital platforms in spreading knowledge, and how EMS professionals can stay connected to a broader learning community. EMS Europe can be found here: https://emseurope.org/The 2025 EMS congress can be found here: https://www.emscongress2025.org/Please find a link to the paper mentioned in the episode here: https://www.linkedin.com/posts/european-ems_earlier-this-year-the-european-association-activity-7110352516667592704-8Kxb?utm_source=share&utm_medium=member_ios&rcm=ACoAAAP50dMB5y9DijwQUZNfWmSnqRRiXV2b9mUThis podcast is sponsored by PAX.Whatever kind of challenge you have to face - with PAX backpacks you are well-prepared. Whether on water, on land or in the air - PAX's versatile, flexible backpacks are perfectly suitable for your requirements and can be used in the most demanding of environments. Equally, PAX bags are built for comfort and rapid access to deliver the right gear at the right time to the right patient. To see more of their innovative designed product range, please click here:⁠https://www.pax-bags.com/en/⁠

Dr. ANA MARIA SERRANO - Associate Professor - Institute of Education (IE), researcher at the Center for Research in Child Studies (CIEC), University of Minho, Portugal.  Has a degree in Psychology from the University of Coimbra. Holds a master's degree in Early Intervention from the University of Cincinnati, USA, as a Fulbright Scholar, and a PhD in Child Studies, a Special Education specialty from the Institute for Child Studies at the University of Minho. She is a professor in the field of Special Education and developed and coordinates one of the first master's programs in Early Childhood Intervention in Portugal (1996). She is member of the National Association for Early Intervention (ANIP), President of the European Association for Early Intervention –EURLYAID, and a member of the Board of Directors of the International Society of Early Childhood Intervention. And she is part of the National System of Early Childhood Intervention (SNIPI), North Subcommittee's Supervision Nucleus. Lives in a city in the North of Portugal – Braga. https://www.eurlyaid.eu/ https://www.eurlyaid.eu/eciguidebook/ https://www.eurlyaid.eu/wp-content/uploads/2023/07/resources-in-ECI.pdf

Dominique de Werra is an emeritus professor of Operations Research at EPFL (Ecole Polytechnique Federale de Lausanne) in Switzerland. His research fields include Combinatorial Optimization, Graph Theory, Scheduling and Timetabling. After spending a few years as an assistant professor in Management Sciences at the University of Waterloo (Canada) he joined the Math Department of EPFL. He conducted a collection of Operational Research projects (applied as well as theoretical) with a number of industrial partners. He is an associate editor of Discrete Applied Mathematics, Discrete Mathematics, Annals of Operations Research and a member of a dozen of editorial boards of international journals. From 1990 to 2000 Dominique de Werra was the Vice-President of EPFL; he was in charge of the international relations and represented his institution in many academy networks in Europe (like the CLUSTER network of excellence which he chaired). He was also in charge of all education programs of EPFL. He was President of IFORS (the International Federation of Operational Research Societies) from 2010 to 2012. In 1987-1988 he was President of EURO, the European Association of Operational Research Societies. In 1985–1986 he was President of ASRO, the Swiss Operations Research Society. In 1995 he was the laureate of the EURO Gold Medal. He has obtained Honorary Degrees from the University of Paris, the Technical University of Poznan (Poland) and the University of Fribourg (Switzerland). In 2012 he was awarded the EURO Distinguished Service Medal. He published over 200 papers in international scientific journals. He also wrote and edited several books. He was member of many committees in various countries of Europe and America (evaluation of institutions, accreditation, strategic orientation, etc.).

Today, we're looking into how industry associations like the European Association for Geoscientists and Engineers (EAGE) can play an important role in connecting the dots in the complex world of energy. I had a chat with Artem Kotenev, the president of the Oslo chapter of EAGE, who shares his insights on how EAGE is stepping up to bridge gaps between traditional oil and gas expertise and the growing field of renewable energy. We explore the exciting developments at EAGE, including new courses and conferences aimed at helping members adapt to this rapidly changing landscape.Links referenced in this episode:eage.orgConnect with Artem on LinkedInEAGE Oslo Chapter on LinkedInstoriesforthefuture.com

In this episode Cath was joined by Dr Kathrin Stauffer. They chatted about how the body remembers in multiple ways and how not getting what we need in childhood impacts multiple systems in our bodies (not just the nervous system). When we are on a healing journey the expression of sadness and grieving are an important part of this journey. However, it may be that we are blocked from crying by our defences. We dived into this and talked about food, body shape, body psychotherapy, the the function of comfort eating, shame and much more. Kathrin Stauffer PhD, UKCP Registered Body Psychotherapist, is the author of ‘Emotional Neglect and the Adult in Therapy: Lifelong Consequences to a Lack of Early Attunement' (W.W. Norton 2020).Kathrin was born and educated in Switzerland. Originally a research biochemist, she retrained at the Chiron Centre for Body Psychotherapy. She lives in Cambridge in the UK and works in private practice as a body and humanistic psychotherapist, EMDR practitioner, trainer and supervisor. She previously wrote ‘Anatomy & Physiology for Psychotherapists: connecting Body & Soul' (W.W. Norton 2010). Currently she is the President of the European Association for Body Psychotherapy EABP.You can contact her via her website which is www.stauffer.co.uk.If you're enjoying this podcast. Please leave a review and rate the podcast, this really helps others to find it.To sign up for the journal prompts and Nurture.Heal.Grow (on Substack) please head to www.cathcounihan.com or @cathcounihan on Instagram. Follow Cath on social media here:Instagram: @cathcounihanSubstack: Nurture.Heal.GrowFacebook: Cath Counihan Hosted on Acast. See acast.com/privacy for more information.

The Stanford Business School professor Michal Kosinski has spent his career warning about the corrosive impact of technology, and particularly social media, on democratic institutions and individual freedom. The Polish born academic gained notoriety for his research at Cambridge University on how social media data could predict intimate personal traits. His work became particularly relevant during the Cambridge Analytica scandal in 2016, leading to significant legal consequences for Facebook, including a $50 billion fine. In this KEEN ON conversation with Kosinski, recorded in Munich at DLD, he emphasizes that Facebook wasn't inherently malicious but failed to understand the full implications of their intrusive technology. Kosinksi connects social media's rise with the growth of populism, explaining how platforms enabled figures like Trump and even Bernie Sanders to bypass traditional political gatekeepers. Kosinski also discusses his controversial 2017 research showing that AI can predict personal characteristics, including sexual orientation, from facial features. On privacy, Kosinski believes that complete privacy protection may be impossible in the modern digital age. Instead, he advocates for building social and legal systems that make privacy invasions less dangerous. Looking to the future, Kosinski expresses short-term optimism about AI's potential to improve lives but long-term concern about the risks of artificial general intelligence (AGI). He notes that while we may see increased prosperity and advancement in the near future, the exponential acceleration of technological progress means long-term risks could materialize much sooner than expected.Michal Kosinski is an Associate Professor of Organizational Behavior at Stanford Graduate School of Business. His research interests encompass both human and artificial cognition. His current work centers on examining the psychological processes in Large Language Models and leveraging Artificial Intelligence, Machine Learning, Big Data, and computational techniques to model and predict human behavior. He co-authored Handbook of Social Psychology and Modern Psychometrics, two popular textbooks, and has published over 100 peer-reviewed papers in prominent journals such as Proceedings of the National Academy of Sciences, Nature Computational Science, Psychological Science, Journal of Personality and Social Psychology, Machine Learning, and Scientific Reports, which have been cited over 22,000 times. He is among the Top 1% of the Highly Cited Researchers according to Clarivate. His research has inspired a cover of The Economist, a 2014 theatre production titled “Privacy,” several TED talks, and a video game. It has been featured in thousands of press articles, books, podcasts, and documentaries. He received a Rising Star award from the Association of Psychological Science (2015) and an Early Achievement Award from the European Association of Personality Psychology (2023). He was behind the first press article warning against Cambridge Analytica. His research exposed the privacy risks they exploited and assessed the effectiveness of their methods. More about his role in uncovering their actions can be found in Steven Levy's insightful book Facebook: The Inside Story and Sander van der Linden's article, “Weapons of Mass Persuasion.” He earned a PhD in psychology from the University of Cambridge and two master's degrees in psychometrics and social psychology. Before his current appointment, he held positions as a post-doctoral scholar in Stanford's Computer Science Department, Deputy Director of the University of Cambridge Psychometrics Centre, and a researcher in Microsoft Research's Machine Learning Group.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

Why do we have countries? Why do we mark this land and these people as distinct from that land and those people? What are countries for? Yii-Jan Lin (Associate Professor of New Testament, Yale Divinity School) joins Matt Croasmun to discuss her new book, Immigration and Apocalypse, which traces the development of distinctly American ideas about the meaning of a country, its borders, and crossing those borders through immigration—exploring how the biblical book of Revelation has influenced our modern geopolitical map.Together they discuss the eschatological vision of Christopher Columbus; the Puritanical founding of New Haven, Connecticut to be the New Jerusalem; Ronald Reagan's America as “City on a Hill”; the politics of COVID; the experience of Asian American immigrants in the 19th century; and how scripture shapes the American imagination in surprising and sometimes troubling ways.About Yii-Jan LinYii-Jan Lin is Associate Professor of New Testament at Yale Divinity School. She specializes in immigration, textual criticism, the Revelation of John, critical race theory, and gender and sexuality. Her book *Immigration and Apocalypse: How the Book of Revelation Shaped American Immigration* (Yale University Press 2024), focuses on the use of Revelation in political discourse surrounding American immigration—in conceptions of America as the New Jerusalem and of unwanted immigrants as the filthy, idolatrous horde outside the city walls.Her book The Erotic Life of Manuscripts (Oxford 2016), examines how metaphors of race, family, evolution, and genetic inheritance have shaped the goals and assumptions of New Testament textual criticism from the eighteenth century to the present.Professor Lin has been published in journals such as the Journal of Biblical Literature, Early Christianity, and TC: A Journal of Biblical Textual Criticism. She is co-chair of the Minoritized Criticism and Biblical Interpretation section of the Society of Biblical Literature, on the steering committee for the Ethnic Chinese Biblical Colloquium, and on the steering committees for the New Testament Textual Criticism and the Bible in America sections of SBL. She also serves on the editorial board of the Journal of Biblical Literature. Professor Lin is a member of the Society of Asian Biblical Studies, the European Association of Biblical Studies, and an elected member of Studiorum Novi Testamenti Societas.Show NotesGet your copy of *Immigration and Apocalypse: How the Book of Revelation Shaped American Immigration, by* Yii-Jan LinIllustration: “John of Patmos watches the descent of New Jerusalem from God in a 14th-century tapestry”—modified and collaged by Evan RosaChristopher Columbus's eschatological visionThe Book of Revelation and the heavenly cityThe meaning of “apocalypse”New Haven as New JerusalemJohn Davenport (April 9, 1597 – May 30, 1670) was an English Puritan clergyman and co-founder of the American colony of New Haven.Ronald Reagan and America as a “shining city on a hill”America as God's cityRevelation 21, The New Jerusalem“A door that's always open”1983 as the “Year of the Bible”Exclusion, open gates, and America's immigration policyHospitalityOutside the gates“For some reason, the seer doesn't see just an open  landscape. He sees these definite walls and definite  gates, even though they're open.”The book of deeds and the book of lifeBureaucracy, and entry and exclusion into heavenThe Good PlaceWhat was immigration like in the Greco-Roman world?Citizenship lists, registrations, and ways of keeping people out“If Heaven Has a Gate, a Wall, and Extreme Vetting, Why Can't America?“Steve King's tweet in  2019, “Heaven Has a Wall, a Gate, and Strict Immigration Policy, Hell Has Open Borders.”Disease and exclusion (COVID-19)Disease came from colonizers“Disease as a divine act to clear the land”Chinese exclusion from AmericaMexican exclusion from AmericaICE was created to enforce laws explicitly excluding Chinese immigrantsFilm: An American Tail“The British Invasion”China, Enemy of the West, and the Dragon of Revelation 12Buddha and the dragon vs the whore of Babylon riding a beast“Do American political ideas about immigration start to frame American theological imaginations about the world to come?”God's kingdom and “Empire”Fears that feed from theological to political registers“What should a Christian posture towards contemporary questions of immigration be?”Xenophobia and fear of the strangerFinality and satisfactionThe theological error of identifying America with the New JerusalemProduction NotesThis podcast featured Yii-Jan LinEdited and Produced by Evan RosaHosted by Evan RosaProduction Assistance by Alexa Rollow, Emily Brookfield, Zoë Halaban, and Kacie BarrettA Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/aboutSupport For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give

Today, we're tackling one of the most important topics for location-independent therapists: liability insurance for traveling therapists. It's the #1 question I get asked in my Facebook group—“What do I do about liability insurance?”—and for good reason. Practicing across state lines or internationally can be confusing, and knowing how to protect yourself, your clients, and your practice is non-negotiable. In this episode, we'll dive into the ins and outs of liability insurance, explore how to stay compliant with licensing laws, and share tips for simplifying your portable practice.What You'll Learn in This Episode:Why liability insurance is essential for therapists, especially those with a traveling lifestyleKey considerations when choosing the right insurance provider (including CPH & Associates and HPSO).How to ensure compliance with your state licensing laws while practicing remotely.The challenges of practicing internationally and how to navigate local laws and insurance options.Tips for simplifying compliance, including keeping detailed records and leveraging professional associations.Mentioned in the Episode:Portable Practice Method: www.kymtolson.kartra.com/page/PP-WaitlistCPH & Associates: https://cphins.com/HPSO (Healthcare Providers Service Organization): https://www.hpso.com/International Therapist Directory: https://internationaltherapistdirectory.com/European Association for Psychotherapy: https://www.europsyche.org/_____________________Connect with me: Instagram: @thetravelingtherapist_kym The Traveling Therapist Facebook Group: www.facebook.com/groups/onlineandtraveling/ The Traveling Therapist Website & Offers:www.thetravelingtherapist.com _____________________ Sponsored by Berries: Say goodbye to the burden of mental health notes with automated note and treatment plan creation! www.berries.icu/therapists Sponsored by Alma: Alma is on a mission to simplify access to mental health care by focusing first and foremost on supporting clinicians. https://helloalma.com/kym

Contributor: Megan Hurley, MD Educational Pearls: Fevers Tylenol Up until 20 weeks NSAIDs are ok but after 20 weeks they are contraindicated Can limit the amount of amniotic fluid produced Can lead to growth restriction Can cause premature closure of the ductus arteriosus Cough Cough drops Humidifier Guafenesine and dextromethorphan (Mucinex) is not well studied but is probably ok with caution in certain circumstances such as post-tussive emesis causing poor PO intake and weight loss Congestion Flonase (Fluticasone nasal spray) Nasal rinses Humidifier 1st generation anti-histamines (Diphenhydramine, Doxylamine, etc.) However, these tend to have more side effects such as fatigue, drowsiness, and dizziness Concider switching to a 2nd generation (Cetirizine, Loratidine, etc.) during the day Disease specific treatments Flu (A and B) gets tamiflu (Oseltamivir) Covid gets paxlovid (Nirmatrelvir/ritonavir) Antibiotics for suspected pneumonia Additional recommendations Elevating the head of bed Nasal strips Stay well hydrated Tea Ice chips Echinacea Zinc Rest Avoid NSAIDs Pseudophedrine Afrin (Oxymetazoline) Combined meds in general References Antonucci, R., Zaffanello, M., Puxeddu, E., Porcella, A., Cuzzolin, L., Pilloni, M. D., & Fanos, V. (2012). Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Current drug metabolism, 13(4), 474–490. https://doi.org/10.2174/138920012800166607 Black, E., Khor, K. E., Kennedy, D., Chutatape, A., Sharma, S., Vancaillie, T., & Demirkol, A. (2019). Medication Use and Pain Management in Pregnancy: A Critical Review. Pain practice : the official journal of World Institute of Pain, 19(8), 875–899. https://doi.org/10.1111/papr.12814 D'Ambrosio, V., Vena, F., Scopelliti, A., D'Aniello, D., Savastano, G., Brunelli, R., & Giancotti, A. (2023). Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: a review. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 36(2), 2253956. https://doi.org/10.1080/14767058.2023.2253956 Summarized by Jeffrey Olson MS3 | Edited by Meg Joyce, MS1 & Jorge Chalit, OMS3  

In this eye-opening episode, I'm tackling some of the biggest fitness myths that have been holding you back from achieving real results—misconceptions that have been circulating for decades! We'll uncover the truth behind common beliefs about weight loss, muscle building, and effective exercise strategies. Prepare to have your fitness worldview challenged as we explore why some widely accepted "rules" might actually be hindering your progress. I'll explain how certain types of training can boost your metabolism, help you burn more fat, and keep your insulin sensitivity in check—all crucial factors as we age. We'll also bust a long-standing myth about weightlifting that particularly affects women, revealing the science behind muscle growth and why you shouldn't fear certain exercises. You'll hear personal stories from my own fitness journey—including a pivotal moment in grad school when I first encountered some of this misguided advice—and how changing my approach transformed my body and energy levels for the better. If you've ever felt frustrated by slow progress or confused by conflicting fitness advice, this episode is a must-watch. We'll discuss how muscle acts as your body's natural shaper and calorie burner, even when you're at rest. My goal is to help you make smarter, more effective choices that work for your unique body—without wasting time on outdated advice! Don't miss this episode! Tune in to learn why it's time to ditch the myths and transform your fitness routine for good. Be sure to subscribe and share your own fitness experiences in the comments—let's get this conversation started!   Full show notes:https://www.jjvirgin.com/5myths Study: The Effect of Resistance Training in Healthy Adults on Body Fat Percentage, Fat Mass and Visceral Fat: A Systematic Review and Meta-Analysis: https://link.springer.com/article/10.1007/s40279-021-01562-2 Study: Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group: https://onlinelibrary.wiley.com/doi/10.1111/obr.13273 Study: Moderate Exercise Attenuates the Loss of Skeletal Muscle Mass That Occurs With Intentional Caloric Restriction–Induced Weight Loss in Older, Overweight to Obese Adults: https://academic.oup.com/biomedgerontology/article/64A/5/575/633506 Study: Moderate and Higher Protein Intakes Promote Superior Body Recomposition in Older Women Performing Resistance Training: https://journals.lww.com/acsm-msse/fulltext/2022/05000/moderate_and_higher_protein_intakes_promote.11.aspx Study: The effect of exercise-training on resting metabolic rate in lean and moderately obese individuals: https://www.semanticscholar.org/paper/The-effect-of-exercise-training-on-resting-rate-in-Tremblay-Fontaine/14c63662ea431c19dc80d41c6eae7c9e0bfbdb74 Reignite Wellness™ Clean Creatine Powder: https://reignitewellness.com/products/clean-creatine-powder Reignite Wellness™ Amino Power Powder: https://reignitewellness.com/products/amino-power-powder Reignite Wellness™ All-In-One Shake Protein Powder: https://reignitewellness.com/search?options%5Bprefix%5D=last&q=protein+shake 7-Day Eat Protein First Challenge: http://jjvirgin.com/proteinfirst Download my free Resistance Training Cheat Sheet: https://jjvirgin.com/resistance TRX Resistance Training Equipment: Free Shipping on all orders $99+: https://www.avantlink.com/click.php?tt=ml&ti=931205&pw=347877 Episode Sponsors:  Try Timeline: https://www.timelinenutrition.com/shop?rfsn=7082975.4b75243 Use code JJ10 for 10% off all products Go to qualialife.com/VIRGINWELLNESS to try Qualia risk-free for up to 100 days and code VIRGINWELLNESS for an additional 15% off.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom CGM is worn in space, two over-the-counter CGMs are now available, a large new study looks at potential dietary causes of type 1, and researchers are looking at a gel version of GLP-1 medications. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Astronauts on the Polaris-Dawn mission are wearing the Dexcom G6 CGM. Polaris Dawn launched this week with astronauts wearing the G6 to better understand the effects of spaceflight on human health. The crew intends to conduct research to advance human health on Earth and the understanding of health during long-duration spaceflights. “This health research-driven mission marks another first for Dexcom, with our industry-leading CGMs being worn by astronauts in outer space,” said Jake Leach, EVP and COO at Dexcom. “We are thrilled to play a role in building a future where people with diabetes are empowered to accomplish anything they set their minds to–including the possibility of exploring outer space–without being held back by their condition.” Over five days in space, the Polaris Dawn crew plans to conduct around 40 scientific experiments. That includes several aimed at better understanding the effects of spaceflight on glucose health. Labront, a platform assisting health researchers in collecting and analyzing physiological data, is collaborating with Dexcom. It plans to provide advanced analytics for the data collected by the crew.   According to a news release, the mission expects to explore how microgravity, fluid shifts, and blood flow restriction exercises impact glucose regulation. https://www.drugdeliverybusiness.com/dexcom-cgm-outer-space-polaris-dawn/ XX There are now two OTC CGMs.. Dexcom launched Stelo a few weeks ago and now Abbott says Lingo is for sale. They're both available on the companies' websites, cost about the same, but you can opt to buy only one Lingo where Stelo comes in pairs. Lingo is meant for people without diabetes – it's a health bio sensor. Abbott has another CGM called Libre Rio meant for people with type 2 who don't take insulin. Not a lot of details about what the real difference are here – likely just in the software – No word on when Rio will be available. https://www.cnbc.com/2024/09/05/-abbott-launches-its-first-over-the-counter-continuous-glucose-monitor-in-the-us.html XX Warning about flying with an insulin pump – And I want to be clear here because I'm sure you'll see some scary headlines. This is really about pressure emergencies in planes. For the study, researchers tested 26 insulin pumps in a hypobaric chamber programmed to mimic the atmospheric changes during a normal commercial airline flight. “The drop in cabin pressure during ascent may lead to a slight increase in insulin delivery as a result of the formation of air bubbles which displace excess insulin out of the cartridge,” Fan said in a meeting news release. “A slight reduction in insulin delivery is also possible during descent as the increasing air pressure dissolves the air bubbles, sucking insulin back into the pump.” People on insulin pumps could be in real trouble in the event of rapid decompression of the cabin at altitude, researchers said. In that case, the pumps could deliver an insulin overdose -- dropping blood sugar levels so much that there's a significant risk of hypoglycemia, results show. These researchers recommend disconnecting and reconnect at take off and landing, but that's not going to help if there is emergency rapid decompression. As always, be prepared with emergency glucagon and low snacks and supplies. https://www.healthday.com/health-news/diabetes/flying-could-upset-insulin-pump-function-for-type-1-diabetics XX Lilly moves forward with it's version of once weekly basal insulin. Clinical trials show it can help control both Type 1 and Type 2 diabetes as well as daily basal injections do. However, in those with type 1 diabetes, there was an increased risk for hypoglycemia.  This is the same issue with Novo Nordisk's Awiqli insulin – approved in Canada but not in the United States. https://www.upi.com/Health_News/2024/09/11/weekly-insulin-injections-effective-diabetes-weekly/8711726068680/ https://www.medscape.com/viewarticle/once-weekly-insulin-looks-good-t2d-risk-seen-t1d-2024a1000gh8 XX Eating what seems like really healthy foods could be associated with a higher risk of developing type 1 diabetes. New study shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition. What triggers the immune system's attack is unknown but is thought to involve a combination of a genetic predisposition and an environmental trigger such as a virus or foodstuff. T1D, the most common form of diabetes in children, is increasing worldwide. The number of cases worldwide is projected to double in just 20 years, from 8.4 million in 2021 to 17.4 million by 2040. Finland has the highest incidence of T1D globally, with 52.2 cases per 100,000 children under the age of 15 – more than five times higher than in the 1950s. 5,674 children (3,010 boys and 2,664 girls) with genetic susceptibility to T1D were followed from birth to the age of six. Food records completed by their parents repeatedly from the age of three months to 6 years provided information on the entire diet.   The 34 food groups covered the entire diet and, when they were all factored in, several foods were associated with a higher risk of developing T1D.   To the best of our knowledge, this is the first time a child's entire diet has been considered at the same time." The results show that the more fruit, oats or rye children ate, the more their risk of T1D increased. In contrast, eating strawberries, blueberries, lingonberries, raspberries, blackcurrants and other berries appeared to provide protection against T1D. The more berries a child ate, the less likely they were to develop T1D. Oats, bananas, fermented dairy products (such as yogurts) and wheat were associated with an increased risk of islet autoimmunity, whereas cruciferous vegetables, such as broccoli, cauliflower and cabbage, were associated with decreased risk. It is, however, too early to make any dietary recommendations. The researchers are quick to point out that they don't really know the “why” here. Could be the food itself, could be pesticides, and until the results are replicated they urge parents not to change their child's diet. https://www.news-medical.net/news/20240909/Eating-fruit-oats-and-rye-in-childhood-may-increase-type-1-diabetes-risk.aspx XX Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying diabetes and weight management Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is a GLP-1 receptor agonist that helps to regulate blood sugar levels and promote weight loss. This medication is especially effective in managing type 2 diabetes and is available in both injectable and oral forms. Semaglutide enhances the body's natural ability to control blood glucose and reduce appetite, providing a dual approach to treatment.     The new hydrogel delivery platform uses two innovative degradable polymers that are chemically bound to one another to form a gel, but allow slow, sustained release of soluble peptides over 1 to 3 months. How do you slow release a gel? With an injection. It goes under the skin. This is still in animal studies, so we're a ways off from human clinical trials. https://scitechdaily.com/new-semaglutide-hydrogel-say-goodbye-to-weekly-shots-for-diabetes-and-weight-loss/ XX   Edgepark Commercial XX   Embecta has received clearance from the Food and Drug Administration for its first insulin patch pump. The device can be used by people with Type 1 or Type 2 diabetes and worn for up to three days. It includes a 300-unit insulin reservoir. Embecta said Tuesday it plans to develop a closed-loop version of the pump for automated insulin dosing that it will submit to the FDA in the future using the Tidepool Loop algorithm. Earlier this summer, Insulet received FDA clearance to offer its Omnipod 5 pump to people with Type 2 diabetes. Diabetes tech firms have focused on Type 2 in recent years as insurance coverage improves. https://www.medtechdive.com/news/embecta-gets-fda-nod-for-insulin-patch-pump/725904/ XX An artificial intelligence (AI)–driven voice algorithm showed "excellent agreement" with the American Diabetes Association (ADA) risk test in detecting adults with type 2 diabetes (T2D), research presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting revealed.   The AI model detected T2D with 66% accuracy among women and 71% in men, and there was 93% agreement with the questionnaire-based ADA risk score, demonstrating comparable performance between voice analysis and an accepted screening tool.   The Colive Voice project includes volunteers from all over the world; however, the current study was restricted to adults from the United States, both with and without T2D, "This first proof of concept was limited to English speakers, and further research will need to enroll more diverse populations, in terms of languages and sociodemographic background," he said. "This study represents a first step toward using voice analysis as a first-line, highly scalable T2D screening strategy," the authors concluded. "The next studies will have to demonstrate the robustness of our approach in diverse populations and also include people living with prediabetes," Fagherazzi said. "If proven reliable, we expect such technology to be available in the next 5-10 years. Then, it could be deployed easily at scale in millions of smartphones worldwide and reduce undiagnosed diabetes cases." https://www.medscape.com/viewarticle/ai-voice-analysis-diabetes-screening-shows-promise-2024a1000ggw XX Join us again soon!